Key facts
- Triton Therapeutics’s last known valuation is $43.5M (Oct 2025).
- It has raised $36.3M across 1 recorded rounds; the latest was Early Stage VC ($36.4M) in Oct 2025.
- Notable investors include Cure Ventures.
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Triton Therapeutics
Funding rounds
1 roundsAbout Triton Therapeutics
Developer of therapeutic compounds intended to address autoimmune and fibrotic medical conditions. The company platform engages in the clinical-stage research and development of novel medical agents that precisely target the underlying disease pathways, enabling patients with complex chronic diseases to access treatment options with the potential to significantly modify the disease course and improve long-term health outcomes.
- Sector
- Healthcare
- HQ
- Stamford, CT, United States
- Founded
- 2025
- Ownership
- Privately Held (backing)
Triton Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Triton Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Triton Therapeutics in its N-PORT filings yet. We sweep new filings monthly.